Ilyang Pharmaceutical company was selected as the final on the vaccine contest for a new type of influenza H7N9
Ilyang Pharmaceutical (CEO Kim, Dong-Youn) was selected as the final on the vaccine contest for a new type of influenza H7N9 from 'Governmental department business unit for new influenza'.
Ilyang has proceeded with fundamental research of H7N9 avian influenza extensively, and has prepared rapid ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
